EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan

Vandana Veenit, Hiddo J L Heerspink iD, Christine Ahlström, Peter J Greasley, Stanko Skritic, Natalie van Zuydam, Donald E Kohan, Pernille B L Hansen, Robert I Menzies

Nephrology Dialysis Transplantation · 29.09.2023 · 38 (10) · 2289-2297

DOI: 10.1093/ndt/gfad078 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 26.04.2023. Verfasst von Vandana Veenit und 8 weiteren Autor:innen. Beteiligte Einrichtung: Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Swede…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic, Symporters, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Endothelin A receptor antagonists (ETARA) slow chronic kidney disease (CKD) progression but their use is limited due to fluid retention and associated clinical risks. Sodium–glucose co-transporter 2 inhibitors (SGLT2i) cause osmotic diuresis and improve clinical outcomes in CKD and heart failure. We hypothesized that co-administration of the SGLT2i dapagliflozin with the ETARA zibotentan would mitigate the fluid retention risk using hematocrit (Hct) and bodyweight as proxies for fluid retention.

Methods

Experiments were performed in 4% salt fed WKY rats. First, we determined the effect of zibotentan (30, 100 or 300 mg/kg/day) on Hct and bodyweight. Second, we assessed the effect of zibotentan (30 or 100 mg/kg/day) alone or in combination with dapagliflozin (3 mg/kg/day) on Hct and bodyweight.

Results

Hct at Day 7 was lower in zibotentan versus vehicle groups [zibotentan 30 mg/kg/day, 43% (standard error 1); 100 mg/kg/day, 42% (1); and 300 mg/kg/day, 42% (1); vs vehicle, 46% (1); P < .05], while bodyweight was numerically higher in all zibotentan groups compared with vehicle. Combining zibotentan with dapagliflozin for 7 days prevented the change in Hct [zibotentan 100 mg/kg/day and dapagliflozin, 45% (1); vs vehicle 46% (1); P = .44] and prevented the zibotentan-driven increase in bodyweight (zibotentan 100 mg/kg/day + dapagliflozin 3 mg/kg/day = –3.65 g baseline corrected bodyweight change; P = .15).

Conclusions

Combining ETARA with SGLT2i prevents ETARA-induced fluid retention, supporting clinical studies to assess the efficacy and safety of combining zibotentan and dapagliflozin in individuals with CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicSymportersDiabetes Mellitus, Type 2AnimalsRatsEndothelin A Receptor AntagonistsReceptor, Endothelin ARats, Inbred WKYBenzhydryl CompoundsGlucoseSodiumGlucosidesPyrrolidines

Stichwörter der Autor:innen

bodyweightdapagliflozinfluid retentionhematocritzibotentan

Substanzen

Sodium-Glucose Transporter 2 InhibitorsEndothelin A Receptor AntagonistsReceptor, Endothelin ABenzhydryl CompoundsSymportersGlucoseSodiumdapagliflozinGlucosidesZD4054

Autor:innen und Institutionen

  • Bioscience Renal, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • DMPK, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Innovation Strategies & External Liaison, Pharmaceutical Technologies & Development, AstraZeneca, Gothenburg, Sweden; Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Institute of Medicine at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

ORCID-Profile: Hiddo J L Heerspink

Förderung

  • AstraZeneca

Zitieren

APA

Veenit, V., Heerspink, H. J. L., Ahlström, C., Greasley, P. J., Skritic, S., van Zuydam, N., Kohan, D. E., Hansen, P. B. L., & Menzies, R. I. (2023). The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrology Dialysis Transplantation, 38(10), 2289-2297. https://doi.org/10.1093/ndt/gfad078

Vancouver

Veenit V, Heerspink HJL, Ahlström C, Greasley PJ, Skritic S, van Zuydam N, et al. The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan. Nephrology Dialysis Transplantation. 2023;38(10):2289-2297. doi:10.1093/ndt/gfad078

BibTeX
@article{Veenit2023,
  author = {Veenit, Vandana and Heerspink, Hiddo J L and Ahlström, Christine and Greasley, Peter J and Skritic, Stanko and van Zuydam, Natalie and Kohan, Donald E and Hansen, Pernille B L and Menzies, Robert I},
  title = {The sodium glucose co-transporter 2 inhibitor dapagliflozin ameliorates the fluid-retaining effect of the endothelin A receptor antagonist zibotentan},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  volume = {38},
  number = {10},
  pages = {2289--2297},
  doi = {10.1093/ndt/gfad078}
}
Kostenlos starten →